Search alternatives:
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a mean » _ mean (Expand Search)
Showing 941 - 960 results of 117,423 for search '(( a mean decrease ) OR ( 5 ((((ng decrease) OR (a decrease))) OR (nn decrease)) ))', query time: 1.40s Refine Results
  1. 941
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  2. 942
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  3. 943
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  4. 944
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  5. 945
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  6. 946
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  7. 947
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 948
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 949
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 950
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 951
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 952
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 953
    IL-17A inhibits apoptosis of OCPs.

    IL-17A inhibits apoptosis of OCPs. by Hao Tang (44155)

    Published 2023
    Save to List
    Saved in:
  14. 954
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 955
    D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis.

    D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. by Kristine C. McGrath (8269155)

    Published 2020
    Save to List
    Saved in:
  16. 956
    D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis.

    D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. by Kristine C. McGrath (8269155)

    Published 2020
    Save to List
    Saved in:
  17. 957
    Testicular involution prior to sex change in gilthead seabream is characterized by a decrease in DMRT1 gene expression and by massive leukocyte infiltration-3

    Testicular involution prior to sex change in gilthead seabream is characterized by a decrease in DMRT1 gene expression and by massive leukocyte infiltration-3 by Sergio Liarte (75701)

    Published 2011
    “…<p><b>Copyright information:</b></p><p>Taken from "Testicular involution prior to sex change in gilthead seabream is characterized by a decrease in DMRT1 gene expression and by massive leukocyte infiltration"</p><p>http://www.rbej.com/content/5/1/20</p><p>Reproductive Biology and Endocrinology 2007;5():20-20.…”
    Save to List
    Saved in:
  18. 958
    eIF5a is up-regulated in unruptured AAAs and decreased in ruptured AAAs.

    eIF5a is up-regulated in unruptured AAAs and decreased in ruptured AAAs. by Dong Ma (584680)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  19. 959
    NCM exposure increases hepatic creatine kinase activity and total ATPase activity, which is associated with decreases in hepatic ABCA1, CD36, and L-FABP protein expression and circulating levels of cholesterol and triglycerides.

    NCM exposure increases hepatic creatine kinase activity and total ATPase activity, which is associated with decreases in hepatic ABCA1, CD36, and L-FABP protein expression and circ... by Ryan J. Mailloux (50825)

    Published 2014
    Subjects: “…mitochondrial ATP synthase subunit ATP 5A…”
    Save to List
    Saved in:
  20. 960
    Three Ca<sub>V</sub>3.3 variants left-shift the window current, while the A398V completely abolishes the window current.

    Three Ca<sub>V</sub>3.3 variants left-shift the window current, while the A398V completely abolishes the window current. by Yousra El Ghaleb (22075892)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: